Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Metabolic DBA, Grenzacherstrasse 124, Basel, Switzerland.
Curr Vasc Pharmacol. 2012 Jul;10(4):422-31. doi: 10.2174/157016112800812683.
Hyperalphalipoproteinemia, as observed in patients who are either homozygous or heterozygous for cholesteryl ester transfer protein (CETP) deficiency, has been shown to be associated with striking changes in apolipoprotein size distribution, namely, of high-density lipoprotein (HDL) and HDL-like particles. We compared the effect of varying degrees of CETP activity on the HDL apolipoprotein profile in Caucasian CETP-deficient subjects and following pharmacological decrease in CETP activity, using Size Exclusion Chromatography followed by Reverse Phase Protein Array (SEC RPA). The main HDL-associated apolipoproteins (Apo), i.e. ApoA-I, ApoA-II, ApoC-I, and ApoC-III, co-eluted with the HDL peak. The presence of a HDL-like peak migrating between the ApoB-LDL and ApoA-I-HDL was identified in a Caucasian patient with homozygosity for a point mutation in exon 2 of the CETP gene (c.109 C > T) resulting in a premature termination codon (R37X) and complete CETP deficiency. This HDL-like peak was not observed either in healthy volunteers treated with the CETP modulator dalcetrapib, patients heterozygous for the same mutation, or in patients heterozygous with G165X mutations. SEC RPA offers the possibility to investigate the distribution of a large number of apolipoproteins simultaneously under non-denaturing separation in normal and dyslipidemic subjects. This is only limited by the availability of antibodies against specific apolipoproteins to be investigated.
高胆固醇酯转运蛋白(CETP)缺乏症纯合子或杂合子患者表现为高脂蛋白血症,该疾病与载脂蛋白大小分布的显著变化有关,即高密度脂蛋白(HDL)和类似 HDL 的颗粒。我们通过大小排阻色谱法联合反相蛋白阵列(SEC RPA),比较了不同程度 CETP 活性对高加索人群 CETP 缺乏症患者和 CETP 活性降低后 HDL 载脂蛋白谱的影响。主要与 HDL 相关的载脂蛋白(Apo),即 ApoA-I、ApoA-II、ApoC-I 和 ApoC-III,与 HDL 峰共洗脱。在一个 CETP 基因外显子 2 点突变(c.109 C > T)导致提前终止密码子(R37X)和完全 CETP 缺乏的纯合子高加索患者中,鉴定出一种在 ApoB-LDL 和 ApoA-I-HDL 之间迁移的类似 HDL 的峰。在接受 CETP 调节剂 dalcetrapib 治疗的健康志愿者、具有相同突变的杂合子患者或具有 G165X 突变的杂合子患者中均未观察到这种类似 HDL 的峰。SEC RPA 提供了在正常和血脂异常患者中非变性分离下同时研究大量载脂蛋白分布的可能性。这仅受要研究的特定载脂蛋白的抗体可用性限制。